MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
Q2 2026 Adjusted EBITDA1 of $0.9M, the Company’s strongest quarterly performance since 20192 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 Net Revenue of $10.0M, an increase of 11% ve…
SOURCE MediPharm Labs Corp.
For further information, please contact: MediPharm Labs Investor Relations,
1 416.913.7425, [email protected]
Notes and References
- Adjusted EBITDA i…